Audere

Audere and South Africa-Based Medical Diagnostech Partner to Bring Africa’s First Home-Grown COVID-19 Antigen Test to Market with Digital Companion App

Retrieved on: 
Freitag, März 11, 2022
Research, Technology, Infectious Diseases, Software, Philanthropy, Biotechnology, General Health, Health, Foundation, Science, South African Medical Research Council, ISO, HIV, Disease management, Health Products Regulatory Authority, Pregnancy, Department, Partnership, Research, Public health, Machine learning, Google Play, Accreditation, App Store (iOS/iPadOS), Membrane protein, Investment, Technology Innovation Agency, Bill, SAMRC, Department of Science and Innovation, MD, Artificial intelligence, Capsid, Health equity, SAHPRA, Solution, COVID-19, Innovation, Global health, Bill & Melinda Gates Foundation, Immunity, Severe acute respiratory syndrome coronavirus 2, Infection, Malaria, Medical device, Mobile phone, Pharmaceutical industry, Audere, Medical Diagnostech, AUDERE, MEDICAL DIAGNOSTECH

Access to aggregated test data will provide a comprehensive understanding of disease prevalence, enabling more informed surveillance and disease management.

Key Points: 
  • Access to aggregated test data will provide a comprehensive understanding of disease prevalence, enabling more informed surveillance and disease management.
  • As a South African, I have first-hand experience with the test inequity challenges faced by individuals in my country.
  • I feel extreme pride to partner with Medical Diagnostech and support the roll-out of a COVID-19 rapid test made on the continent, for the continent.
  • The increased public health reporting capabilities enabled by digitizing rapid diagnostic test result data are crucial to South Africas evolving public health strategy.

Audere Receives FDA Emergency Use Authorization for HealthPulse@home COVID-19 Specimen Collection Test Kit

Retrieved on: 
Dienstag, Dezember 7, 2021
Medical Supplies, Biotechnology, Practice Management, FDA, Other Health, Health, Philanthropy, General Health, Other Philanthropy, Infectious Diseases, Foundation, COVID-19 testing, Bill & Melinda Gates Foundation, Federal Food, Drug, and Cosmetic Act, Malaria, Laboratory, Health equity, EUA, Disease, Infection, Bill, Collection, Food, Fortis Healthcare, CEO, CMS, Organization, Diabetes, Emergency Use Authorization, Machine learning, HIV, Health, Virus, Maintenance, Time, COVID-19, Degenerative disease, Pharmacy, FDA, LinkedIn, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, News, Solution, Diagnosis, School, Global health, Severe acute respiratory syndrome coronavirus 2, Platform, Pharmaceutical industry, Medical device, Audere, LumiraDx, Previon, AUDERE, LUMIRADX, PREVION

HealthPulse@home provides a faster, less expensive, hassle-free option for laboratories looking to offer COVID-19 specimen collection kits in the United States.

Key Points: 
  • HealthPulse@home provides a faster, less expensive, hassle-free option for laboratories looking to offer COVID-19 specimen collection kits in the United States.
  • Audere also provides recommended vendors and guidance for kit packaging, ordering, and accessioning, helping laboratories quickly bring new tests to market.
  • The solution enables organizations to offer test kits for the unsupervised self-collection or collection by a caregiver of a nasal swab specimen.
  • 1 HealthPulse@home has not been FDA cleared or approved but has been authorized for emergency use by the FDA under an EUA.

Audere Partners with Fred Hutchinson Cancer Research Center, Jhpiego, Jomo Kenyatta University of Agriculture and Technology, MYDAWA, and University of Washington on HIV PrEP Virtual Delivery Study in Kenya

Retrieved on: 
Mittwoch, Dezember 1, 2021
Research, Technology, Infectious Diseases, Software, Practice Management, AIDS, Pharmaceutical, Health, Consumer Electronics, Science, Audere, Fred Hutchinson Cancer Research Center, Jhpiego, Jomo Kenyatta University of Agriculture and Technology, MYDAWA, University of Washington, AUDERE, FRED HUTCHINSON CANCER RESEARCH CENTER, JHPIEGO, JOMO KENYATTA UNIVERSITY OF AGRICULTURE AND TECHNOLOGY, MYDAWA, UNIVERSITY OF WASHINGTON

As part of this study, HIV self-tests will be examined as a tool to determine eligibility for PrEP.

Key Points: 
  • As part of this study, HIV self-tests will be examined as a tool to determine eligibility for PrEP.
  • Audere is eager to work with its study partners to explore the boundaries of how to expand, innovate, and improve care delivery for HIV.
  • This study involves partners across the global health space that will jointly design and execute a new end-to-end virtual care delivery model for HIV.
  • The University of Washington, in partnership with Fred Hutchinson Cancer Research Center and Jomo Kenyatta University of Agriculture and Technology, will lead the studys research design, data collection, analysis, and dissemination.